The demand from regulators and payers for health economic models is increasing, as these key decision makers struggle to manage budget constraints and provide access to new therapies.
Health economic models are required to demonstrate product value and support reimbursement submissions; however, early economic models (EEMs) can also be used to inform clinical development decisions, develop HEOR and real world evidence (RWE) generation planning and support early pricing and market access discussions.
Join us to learn best practices for developing early economic models to inform key strategic decisions. Through discussion and a case study, get insights on:
- Types of early economic models and why are they important
- Guidelines on their development and the selection of data sources
- Case-examples of use in evidence strategy generation
- How early economic models are used to identify evidence gaps
Healthcare decision makers around the world are increasingly requiring information on cost-effectiveness of new therapies as they struggle for ways to manage their budgets while providing access. Such cost-effectiveness evaluations generally require Phase III clinical data and are conducted at the time of product launch. However, conducting such evaluations early in the clinical development process can identify gaps in evidence, help in internal pricing discussions, inform clinical trial development decisions, inform RWE generation planning and identify which parameters are most influential to reimbursement decisions.
The lack of certainty between the data at launch and a drug’s ongoing clinical performance expectations are key clinical and reimbursement concerns for both HTA reviewers and the payers they influence. Early modelling can help to fill the gap between the data currently available and the expected long term clinical, economic, and humanistic outcomes.
Register today to learn more about using early economic modelling to better reflect the evolution of new therapies, to enhance the commercialisation of these therapies, and to effectively communicate the value of these therapies to all key decision makers.
Victoria Paly, MHS, Senior Health Economist, ICON
Victoria Paly has worked in HEOR for over 6 years supporting the development of effective value propositions for pharmaceutical products. She has extensive experience in retrospective database analysis and economic modeling, including development of cost-effectiveness analyses to support HTA submissions.
Dhvani Shah, MS, Lead Health Economist, ICON
Dhvani Shah has over 8 years of experience in HEOR, and has led numerous evidence generation activities to demonstrate and communicate product value. She is responsible for preparing HEOR evidence and value strategies, developing economic models for HTA submissions and conducting literature reviews and evidence synthesis activities.
Who Should Attend?
This program is intended for professionals from pharmaceutical, biotech, and medical device companies involved in:
- Health Economics & Outcomes Research (HEOR)
- Market Access
- Medical Affairs
- Regulatory Affairs
- Pharmacovigilance & Risk Management
ICON Commercialisation & Outcomes, which optimises the value of drugs and medical devices through innovative strategies and tactics to meet evolving evidentiary, regulatory, and reimbursement requirements. Our expert team establishes and communicates a product’s unique clinical and economic outcomes to achieve success in today’s dynamic and patient-centric healthcare environment.